H. Minagawa

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia

T. Shirakawa, A. Tsuboi, K. Ozono, 2023, BMC Cancer.

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies

H. Kishima, Y. Oji, A. Tsuboi, 2021, Neuro-oncology advances.